The MyBrain study investigates the brain function of children, adolescents and young adults during and after chemo treatment for cancer. The tests include 1) cognitive skills such as memory and attention; 2) the brain's electrical activity; 3) and biological markers related to brain function.
The aim of the study is to better understand the trajectories of cognitive functioning and measures that have been associated with cognitive impairment in patients treated with chemotherapy.
Eligibility
Sex
ALL
Min age
7 Years
Max age
29 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Patients who are newly diagnosed with a non-CNS cancer and will undergo chemotherapy at University Hospital Copenhagen, Rigshospitalet.
* At the age of 7-29 years at diagnosis
* Each patient is matched (1:1) with a control participant within 24 months of age. The controls are recruited from the patient's own social circle and can be a friend, partner, or close family (sibling or cousin).
Exclusion Criteria:
* Unable to speak and understand Danish
* Severe intellectual disability or mental health disorder that hinders participation
* Brain metastases,
* Terminal illness
* Have had a previous chemotherapy or radiotherapy treatment
Primary outcome measure(s)
Performance on clinical neurocognitive tests: Wechlers scale — T0: within 30 days of diagnosis Scores on the clinical neurocognitive tests (Wechler Intelligence Scale for Children Fifth edition for participants 7-15.9 years of age, Wechler Adult Intelligence Scale Fourth edition for participants 16 years of age or older). Scaled scores range from 0-19, higher = better performance.
Performance on clinical neurocognitive tests: Wechlers scale — T2: end of treatment (2 weeks after the final antineoplastic treatment) Scores on the clinical neurocognitive tests (Wechler Intelligence Scale for Children Fifth edition for participants 7-15.9 years of age, Wechler Adult Intelligence Scale Fourth edition for participants 16 years of age or older). Scaled scores range from 0-19, higher = better performance.
Performance on clinical neurocognitive tests: Wechlers scale — T3: 6 months after end of treatment Scores on the clinical neurocognitive tests (Wechler Intelligence Scale for Children Fifth edition for participants 7-15.9 years of age, Wechler Adult Intelligence Scale Fourth edition for participants 16 years of age or older). Scaled scores range from 0-19, higher = better performance.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.